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Abstract Receptor accessory peptidyl prolyl cis/trans iso-
merases (PPIases) of the FKBP and cyclophilin types form
receptor heterocomplexes with different stabilities. PPIases have
been found to associate with other receptor heterocomplex
constituents via either proline-directed active sites or additional
domains of the enzymes. The single-domain PPIases FKBP12
and FKBP12.6 are shown to interact with receptor protein
kinases and calcium channels at their active sites. In contrast,
heterooligomeric nuclear receptors contain multi-domain
PPIases like FKBP51, FKBP52 or cyclophilin 40 that directly
interact with the chaperone hsp90 via the tetratricopeptide repeat
modules of the folding helper enzymes. PPIases play a critical
role in the functional arrangement of components within receptor
heterocomplexes. ß 2001 Federation of European Biochemical
Societies. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
The balance of events to regulate receptor protein-mediated
signaling is often maintained by receptor accessory proteins
that form heterooligomeric complexes of di¡erent thermody-
namic stability together with the ligand binding receptor pro-
tein. Among the great variety of accessory proteins, one re-
markable feature is that the folding helper proteins of the
enzyme class of peptidyl prolyl cis/trans isomerases (PPIases,
EC 5.2.1.8) together with chaperones constitute a major part
of the receptor complexes (Fig. 1). PPIases are folding helper
enzymes with the capability to catalyze the cis/trans isomer-
ization of prolyl bonds1 in di¡erent folding states of a target
protein, and this interconversion a¡ects the spatial arrange-
ment of backbone segments in the protein. PPIase-catalyzed
protein conformational changes were shown for the refolding
of denatured proteins [1], de novo protein synthesis [2,3] and
the formation of biologically active conformations of polypep-
tides [4,5]. Obviously, PPIases have to be functional in both
proline-directed polypeptide binding and catalysis of confor-
mational interconversions of proline-containing polypeptide
substrates [6].
The three phylogenetically conserved families of PPIases
involved in catalysis of protein folding are the cyclophilins
(Cyps), the FK506 binding proteins (FKBPs) and the parvu-
lins [7]. The PPIase activity of Cyps is inhibited by the immu-
nosuppressant drug cyclosporin A (CsA), whereas FKBPs are
inhibited by FK506 and rapamycin. Thus, Cyps and FKBPs
have occasionally been termed immunophilins. A major part
of the bioactivity of CsA and FK506 is thought to be medi-
ated by calcineurin inhibition as the consequence of a ‘gain of
function’ mechanism, and the inhibitory potency of the re-
spective PPIase/drug complexes. Generally, it appears that
the gain of function properties of the PPIase/drug complexes
do not explain drug e¡ects on heterooligomeric receptor sig-
naling. The PPIase families comprise members of single-do-
main prototypes as well as much larger proteins with addi-
tional N- or C-terminal domains with a variety of functions.
These include tetratricopeptide repeats (TPR), WW domains,
calmodulin binding sites, DNA binding sites, RNA binding
sites, and dimerization modules.
PPIases have been found to associate with other proteins
either by virtue of their complementary domain interfaces or
at their proline-directed active sites. The above mentioned
enzyme inhibitors and their derivatives can be used to distin-
guish between active site-mediated interactions and associa-
tions directed by peripheral protein regions. However, the
multiplicity of the members of the PPIase families in mamma-
lian cell types may mask the loss of function through func-
tional substitution by another [8]. The single-domain PPIase
FKBP12 and FKBP12.6 active sites interact with receptor
protein kinases and calcium channels. The receptor proteins
themselves are probably substrates for the PPIases. In con-
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trast, the heterooligomeric steroid receptors and the arylhy-
drocarbon receptor (AhR) contain multi-domain PPIases in
direct interaction with the chaperone hsp90 via the TPR mod-
ules of the folding helper enzymes [9]. A comparison of the
characteristics of receptor/PPIase functional interactions can
shed light on the role of structural reorganization of the re-
ceptor protein during ligand-induced signal transfer processes.
2. Interaction of single-domain PPIases with receptors
The endoplasmic reticulum and its tissue-speci¢c derivatives
such as the sarcoplasmic reticulum, the main Ca2 storage
compartment, contain two di¡erent families of Ca2 release
channels, the ryanodine receptors (RyR) and the inositol
1,4,5-trisphosphate receptors (JP3R).
The RyR consists of four identical 565 kDa subunits, there
are three isoforms of RyR. RyR1 is the primary isoform in
skeletal muscles, RyR2 is found in the cardiac sarcoplasmic
reticulum, RyR3 is found in the brain. Puri¢ed RyR1 from
terminal cisternae (TC) of sarcoplasmic reticulum of rabbit
skeletal muscle was found to associate tightly with the proto-
type of the FKBP family of PPIases, the cytoplasmic FKBP12
[10,11]. The 4:1 molar ratio of FKBP12/tetrameric RyR com-
plex indicates the stoichiometric binding of one FKBP12 mol-
ecule to one RyR subunit [11]. The heterocomplex dissocia-
tion by titration with FK506 reveals that the interaction
involves the active site of FKBP12. FKBP12.6, which di¡ers
from FKBP12 in 16 of 107 amino acid residues, can also bind
to RyR1. In cardiac muscle sarcoplasmic reticulum it is spe-
ci¢cally associated with RyR2 [12], selective binding is caused
by Gln31, Asn32 and Phe59 of FKBP12.6 [13].
RyR channels from FKBP12-de¢cient TC vesicles have
greater open probabilities and longer mean open times com-
pared to complete TC [14]. FKBP12-depleted RyR channels
opened frequently to substate levels of V0.25, V0.5, and
V0.75 of the maximum conductance [15]. Functional di¡er-
ences between RyR1 and RyR3 such as skeletal type excita-
tion^contraction-coupled gating behaviors and subconduc-
tance levels are thought to arise from FKBP12 binding [16].
FKBP12 was proposed to mediate interactions between RyR
channels because addition of external FKBP12 to RyR in
planar bilayers induces coupled gating [17]. Dissociation of
FKBP12 from TC by competition with FK520, a non-immu-
nosuppressive structural analogue of FK506, increases the
Ca2 leak rate. Interestingly, substitution by the FKBP12
variants F36Y, W59H and F99Y, which exhibit reduced
PPIase activity, for wild type FKBP12 on the RyR hetero-
complex cannot abolish the wild type FKBP12 e¡ects on the
Ca2 £ux of TC vesicles. These results suggest that either
PPIase activity is unnecessary or the residual enzyme activity
of the FKBP12 variants su⁄ces for the FKBP-mediated mod-
ulation of the calcium release channel [18]. In contrast, Marks
[19] reported that the FKBP12 F36Y variant is still able to
bind, but not to modulate RyR channeling pointing to a cru-
cial role of the unperturbed enzyme activity of FKBP12. Re-
viewing these experiments under standardized conditions
might provide new insights into this discrepancy.
A still unspeci¢ed FKBP is required as a binding partner of
RyR during fertilization of Phallusia mammillata ascidian oo-
cytes [20]. FKBP12-de¢cient mice have normal skeletal muscle
but severe dilated cardiomyopathy and ventricular septal de-
fects [21]. The functional properties of RyR1 as well as of
cardiac RyR2 regarding greater open probability and subcon-
ductance states are typical of FKBP12 shortage. The cardiac
defects of FKBP12-de¢cient mice may demonstrate the inabil-
ity of FKBP12.6 to functionally replace FKBP12 in RyR
signaling. In a canine model of pacing-induced heart failure,
the ratio of FKBP12.6 per RyR2 is signi¢cantly decreased. A
conformational change resulted for RyR2 chains concomitant
with abnormal Ca2 leak of the channel [22]. Protein kinase
A-mediated hyperphosphorylation of RyR in failing human
hearts induces dissociation of FKBP12.6 from RyR thus re-
sulting in defective channel function [23]. Biological data as
well as in vitro experiments reveal the importance of the in-
teraction between the receptor and FKBP12 or FKBP12.6 in
RyR channel function although the mechanism of FKBP
function and the role of PPIase activity of these enzymes in
the heterocomplex are still unsolved problems.
FKBP12 was also found to be a constituent of IP3R, the
other major calcium release channel of the endoplasmic retic-
ulum [24]. FK506 and rapamycin physically disrupt the het-
erocomplex, indicating that the active site of FKBP12 is in-
volved in binding. The IP3R sequence region exhibiting the
FKBP12 active site a⁄nity mapped within the central modu-
latory portion, and the leucyl prolyl moiety of the
1396CNSLLPLDDIV1406 amino acid stretch represents the ac-
tive portion [25]. Surprisingly, the gain of function model of
calcineurin inhibition of the FK506/FKBP12 complex was
mimicked by the FKBP12/IP3R (1349^1460 segment) complex
because calcineurin was found to be an interaction partner of
this complex in a derived yeast two-hybrid system. However,
no calcineurin inhibition was obtained with the FKBP12/IP3R
(1349^1460 segment) complex. Nevertheless, interactions of
FKBP12 with both major calcium release channels of the
endoplasmic reticulum have been shown, which implies that
these interactions play a critical role in calcium signaling.
Apparently, this kind of stable heterocomplex does not
form during the functional interaction of FKBP with receptor
protein kinases, another receptor type in£uenced by PPIases.
The heterodimeric transforming growth factor-L (TGF-L) re-
ceptor consists of the serine/threonine kinase subunits type I
(TLR-I) and type II (TLR-II). Ligand binding enables TLR-II
to recruit and activate TLR-I by phosphorylation of the serine
residues in the glycine/serine-rich domain (GS domain) of the
juxtamembrane region of TLR-I. FKBP12 binds to the cyto-
plasmic domain of unactivated TLR-I in vitro and in vivo.
The Leu193-Pro194 moiety in the juxtamembrane region of
TLR-I, which localizes in close proximity to the activating
phosphorylation sites in the GS domain, is required for the
interaction. This was shown by the site-directed variants of
TLR-I: P194A and L193A/P194A, as well as P194K and
L193G. These variants cannot interact with FKBP12 [26^
28]. On the other hand, the interaction of FKBP12 with
TLR-I does involve the active site of the PPIase. A concen-
tration of 1 WM FK506 prevents association of the two pro-
teins [26]. The crystal structure of the binary complex of an
unphosphorylated TLR-I fragment containing both the GS
region and the catalytic domain and FKBP12 has been deter-
mined. FKBP12 binds to the GS region of the receptor, cap-
ping the TLR-II phosphorylation sites and further stabilizing
the inactive conformation of TLR-I [29].
Overexpression of a myristylated FKBP12 in TGF-L-re-
sponsive mink lung epithelial cells inhibits two separate
TGF-L-dependent signal pathways, as shown by the reduction
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of TGF-L-induced 3TP-Luc luciferase expression and the in-
crease of expression of a cyclin A promoter-driven luciferase
[30]. FKBP12 binding to TLR-I inhibits the receptor activa-
tion in the absence or in the presence of low amounts of TGF-
L, the absence of FKBP12 causes activation of TGF-L recep-
tor (TLR) signaling even in the presence of threshold doses of
TGF-L. Loss of FKBP12 binding properties of the TLR-I
variants L193G and P194K accompanies hypersensitivity to
activation by basal level interactions with TLR-II [31]. Thus,
FKBP12 may serve as a protective agent against leaky signal-
ing resulting from the intrinsic a⁄nity of the TLR subunits by
preventing the activation of TLR-I in the absence of ligand.
Both embryonic ¢broblasts and thymocytes de¢cient in
FKBP12 do not show any di¡erences from wild type cells
with respect to TGF-L-mediated signaling [32]. FKBP12-de¢-
cient mice do not phenocopy any TLR or ligand knockout as
well as the overexpressor mouse model [21]. Considering the
multiplicity of members of FKBP in mammalian cells [8],
functional replacement of FKBP12 provides a convincing ex-
planation for this result. FKBP12 apparently functions as a
negative regulator of TLR endocytosis. Rapamycin speci¢cally
enhances internalization of a chimeric receptor system con-
taining the ligand binding domain of granulocyte-macrophage
colony-stimulating factor receptor fused to TGF-L receptor
transmembrane and cytoplasmic domains [33]. This might in-
dicate that FKBP12 plays a broader role in TLR signaling
than simply inhibiting receptor activation by preventing
TLR-I phosphorylation.
As exempli¢ed by the epidermal growth factor (EGF) re-
ceptor, FKBP12 is inhibitory to the autophosphorylation of a
receptor tyrosine kinase [34]. In many aspects, the e¡ect re-
sembles the inhibition of serine/threonine phosphorylation of
TLR-I, but now extends to tyrosine phosphorylation.
FK506 and rapamycin enhance phosphorylation of EGF
receptor in a comparable manner in EGF receptor-rich
A431 ¢broblasts leading to a decrease in cell growth. In re-
sponse to FKBP12, but not to Cyp18, autophosphorylation of
the EGF receptor is reversibly and completely inhibited at 20
WM FKBP12 in microsomal receptor preparations. Other
PPIases of the FKBP family such as Legionella pneumophila
FKBP25, Escherichia coli FKBP22 and SlyD are also able to
suppress in vitro autophosphorylation of EGF receptor, but
to di¡erent degrees. The FKBP variants D37L and F99Y,
which show reduced PPIase activity but have restored binding
capability, do not a¡ect EGF receptor phosphorylation indi-
cating the importance of PPIase activity in the functional
interaction [44]. Crosslinking experiments reveal direct bind-
ing to EGF receptor dimers by both FKBP12 and FKBP12
D37L. Pulse chase experiments have shown that dephosphor-
ylation of the EGF receptor by intrinsic protein tyrosine phos-
phatases is not in£uenced by FKBP12. Similar to TLR-I phos-
phorylation, the presence of a high concentration of FKBP12
prevents leaky receptor autophosphorylation (C. Schiene-
Fischer, unpublished data). The role of FKBP12 in receptor
protein kinase heterocomplexes and the impact of these com-
plexes on intracellular signaling are emerging as an interesting
component of the conformational regulation of intracellular
signaling mechanism.
A common feature of the single domain FKBP/receptor
heterocomplexes regarding receptor protein kinases and calci-
um release channels is that the PPIase inhibits signaling in a
manner dependent on enzyme catalysis. Obviously, FKBP12
alone cannot shift the putative native-state prolyl isomer ratio
of the receptor, which might cause altered receptor activity,
unless the FKBP12 concentration exceeds that of the receptor.
However, the receptor being trapped in a high-energy, high-
activity state would also provide a hypothesis for the
FKBP12-catalyzed inactivation to occur. Coupling of en-
ergy-driven reactions as receptor phosphorylation or dephos-
phorylation opens a way to produce transient high-energy
prolyl bond conformations that can be released in response
to FKBP12. In fact, single-domain FKBP-mediated receptor
activity was shown to be strongly dependent on the receptor
phosphorylation status, as shown for TLR and RyR.
3. Multi-domain PPIases in heterocomplexes of nuclear
receptors
Unactivated steroid receptor heterocomplexes contain mul-
ti-domain PPIases of the Cyp and FKBP families that are
composed of functional sequence motifs in addition to the
catalytic core (Fig. 2). For these heterocomplexes, three fun-
damental assembly stages can be identi¢ed on the basis of
their unique protein compositions as demonstrated for pro-
gesterone receptor (PR) (Fig. 3). Mature complex formation
requires the recruitment of PPIases. One of the PPIases, either
FKBP51, FKBP52 or Cyp40 [35^37], is bound to hsp90 via
their TPR motifs. These are degenerative sequences of 34
amino acids found to be frequently involved in protein^pro-
tein interactions. The PPIases di¡er in their preferences for
distinct steroid receptor heterocomplexes. The PR heterocom-
plex preferentially assembles with FKBP51 despite its low
Fig. 1. PPIases as components of receptor heterocomplexes of (A) Ca2 release channels, (B) receptor protein kinases, (C) nuclear receptors.
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concentration of 20 nM compared to 100 nM FKBP52 and
200 nM Cyp40 in reticulocyte lysate. The C-terminal region of
the PPIases, which along with the TPR motifs contributes to
hsp90 binding, also includes the speci¢city determinants for
discrimination between the di¡erent steroid receptor hetero-
complexes [38,39]. Competition experiments with C-terminally
truncated hsp90 variants revealed a single TPR recognition
site encompassing a segment between residues 600 and 724
[40,41]. This 124-residue segment, which contains the essential
729EEVD732 sequence motif, overlaps with the hsp90 dimeri-
zation domain and is important for hsp90 binding to the
steroid receptor protein as well. Binding of steroid hormone
to the receptor protein prevents reinitiation of the heterocom-
plex assembly cycle. The steroid receptor migrates to the nu-
cleus and the heterocomplex components dissociate. The ste-
roid receptor protein is now able to form homodimers, which
act as transcription factors that bind to DNA at the hormone
response elements in close proximity to targeted genes. The
heterocomplex form of steroid receptors keeps unactivated
steroid receptors silenced.
Other nuclear receptor proteins found to be associated with
PPIases do not homodimerize in the nuclear, transcriptionally
active form. After ligand activation the ecdysone receptor of
Manduca sexta forms heterodimers with the ultraspiracle pro-
tein resulting in the control of insect metamorphosis. The
FKBP46 that complements the unactivated receptor hetero-
complex is made up of a helical DNA binding domain and a
C-terminal FKBP-like segment but contains no TPR motif
[42,43]. Unliganded cytosolic AhR also exists as a heterocom-
plex. After ligand activation, AhR migrates to the nucleus and
heterodimerizes with Arnt (AhR nuclear translocator protein).
The TPR domain PPIase FKBP37 (also termed AIP, ARA9
or XAP2) speci¢cally associates with hsp90 in the unliganded
AhR heterocomplex. Overexpression of FKBP37 results in an
increase of AhR-mediated transcriptional activity in Hepa1
cells after ligand activation [44,45]. The increasing variety of
nuclear receptor heterocomplexes that have been shown to
contain PPIases suggests the general importance of these fold-
ing helper enzymes in nuclear receptor signaling.
Human FKBP52 (also termed hsp56, p52, FKBP59 or HBI)
consists of three globular domains that could be expressed
separately in E. coli [35] (Fig. 2). Recombinant FKBP52 ex-
hibits PPIase activity mainly due to the N-terminal domain
that is inhibited by FK506 e⁄ciently (Ki = 10 nM) [46]. Casein
kinase II-catalyzed phosphorylation of Thr143, which is situ-
ated in the hinge region between the two FKBP homologous
domains, controls hsp90 binding properties of FKBP52 [47].
The phosphorylated form of FKBP52 cannot maintain hsp90
binding. The main fraction of FKBP52 is located in the nu-
cleus, the cytoskeleton of interphase cells assembles a minor
fraction [48]. Interestingly, it is FKBP52 that was found to
mediate the neuroregenerative properties of FKBP inhibitors,
as was shown by the inhibition of FK506-induced neurite
outgrowth of SHSY5Y cells by monoclonal anti-FKBP52
antibody [49]. However, the mechanism of neuroregeneration
and neuroprotection by PPIase inhibitors is still unknown.
Human FKBP51 (FKBP54, p54, FF1 antigen) was discovered
in the PR heterocomplex [36,38]. It exhibits 55% overall iden-
tity to human FKBP52. Like FKBP52, it has a domain struc-
ture characterized by two FKBP domains and three TPR
motifs (Fig. 2). Additionally, there exists a series of smaller
human FKBPs: FKBP36, FKBP37 and FKBP38, all of which
lack the second FKBP-like domain of FKBP52. PPIase activ-
ity and FK506 binding have not yet been detected for
FKBP37, which is associated with unliganded AhR [50].
The common gene deletion region of the developmental dis-
order Williams syndrome encompasses the human gene fkb6
that encodes the widely expressed FKBP36 [51]. Despite the
presence of the two basic amino acid residues Lys97 and
Arg101 shown to be important for PP5 binding via TPR to
hsp90 [52] in the TPR motifs of FKBP36 and FKBP38, no
association of these proteins to steroid receptor heterocom-
plexes has been found to date. Cyp40 (PPID, CypD) was
discovered in the unactivated bovine estrogen receptor heter-
ocomplex [53]. The N-terminal part of this protein is highly
homologous to human Cyp18 and exhibits CsA-inhibitable
PPIase activity (Fig. 2). The multitude of multi-domain
PPIases found in nuclear receptor heterocomplexes and the
existence of preferences of some PPIases to certain heterocom-
plexes suggest that there is a functional diversity of these
enzymes in nuclear receptor signaling.
In fact, the PPIases are not required for glucocorticoid re-
ceptor (GR)/hsp90 heterocomplex assembly and proper fold-
ing of the hormone binding domain in reticulocyte lysate [54].
Nevertheless, a considerable in£uence of FKBP51 on hor-
mone binding was recently shown. The high level of
FKBP51 in squirrel monkey causes low-a⁄nity hormone
binding of GR in this primate [55]. Coexpression of the hu-
man GR protein and either squirrel monkey FKBP51 or hu-
man FKBP51 in COS-7 cells increases the EC50 of GR trans-
activation by dexamethasone 17-fold and 3-fold, respectively.
This FKBP-mediated inhibition of ligand binding to GR,
which can be abolished by FK506 and rapamycin, suggests
a PPIase-controlled hormone sensitivity of the receptor [56].
As indicated from the colocalization of FKBP52 and the GR
protein in the nucleus during microtubule association, there
may be an FKBP52-mediated linkage of the GR heterocom-
plex to the movement machinery of receptor tra⁄cking be-
Fig. 2. Schematic representation of the structural organization of
PPIases found to be associated with receptors in comparison to the
single-domain prototypes of the respective PPIase family.
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tween cytosol and nucleus [48,57]. In addition, the ¢rst PPIase
domain of FKBP52 binds to the microtubule-associated mo-
tor protein dynein [58]. A common property of PPIases bound
to steroid receptor heterocomplexes beside PPIase activity is
their chaperone activity, which may mediate direct binding to
non-native receptor proteins [59].
Generally, cellular e¡ects of CsA, FK506 and rapamycin
have been used to probe the active site engagement of PPIases
in steroid hormone response. Both CsA and FK506 potentiate
the dexamethasone-induced expression of a CAT reporter
gene in mouse ¢broblasts [60,61], but accumulation of dexa-
methasone in the cytosol was thought to be the cause of the
e¡ect [62,63]. At variance with this hypothesis, hormone re-
sponse showed a similar increase in in vitro experiments that
did not su¡er from e¡ects of the PPIase inhibitors on accu-
mulation and transport processes [64]. The diversity of the
drug binding proteins, the lack of speci¢c inhibitors, and the
multiplicity of the signaling pathways a¡ected make it impos-
sible to draw general conclusions from these data [65].
The widespread existence of multi-domain PPIases in nu-
clear receptor heterocomplexes addresses the general question
of the importance of domains complementing the PPIase core.
For Cyp40, FKBP51, FKBP52 and FKBP37 the additional
TPR is the only common additional motif. The only known
functional consequence of TPR is avidly sequestering hsp90.
For thermodynamic reasons this association would render the
PPIase catalysis more e⁄cient since intermolecular catalysis is
converted to an intramolecular event active in the steroid
receptor complex. Thus hsp90 and the PPIase domains may
act in concert on the receptor protein to keep it in a functional
folding state.
4. Conclusions
Members of the two major enzyme families of PPIases, the
FKBPs and Cyps, have been shown to interact functionally
with three di¡erent types of cellular receptors as nuclear re-
ceptors including steroid receptors and AhR, calcium release
channels, as well as receptor protein kinases. More examples
can be expected to exist. These enzymes are directed to the
multiplicity of di¡erent folding states of proteins in cells. Ob-
viously, several reports have already shown that the biological
function of native, globular proteins is separated by a distinct
prolyl bond isomerization [4,5], but comparable information
is still lacking in heterooligomeric complex and membrane
receptor signaling. Bringing together the recent advances in
the elucidation of the mechanism underlying the conforma-
tional control of protein phosphorylation/dephosphorylation
[66,4] and the e¡ect of PPIases on receptor phosphorylation
has provided a better understanding of the essential steps of
the PPIase-mediated receptor downregulation. Thus, FKBPs
are likely to accelerate slow receptor protein kinase deactiva-
tion rather than cause depletion of the active conformation of
the substrate chain. Despite alterations of the cis/trans isomer
ratio found for the Michaelis complexes of PPIases, these
enzymes cannot shift this ratio under steady-state conditions.
However, in the case of PPIase^receptor interactions, PPIase
is usually present in stoichiometric excess. Therefore, it is
di⁄cult to distinguish the role of PPIases in catalytic events
from their possible function as stoichiometric agents. Because
prolyl isomerizations may occur on the time scale of ligand
binding, or even more slowly, the subsequent conformational
change of a polypeptide chain may become rate-limiting for
signaling and, thus, sensitive to PPIases.
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